Ozempic is a prescription drug developed by Novo Nordisk that contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist
In the UK, NICE technology appraisals (TA875 for semaglutide and TA664 for liraglutide) specify that these treatments should be prescribed within specialist weight management services, with continuation dependent on achieving at least 5% weight loss at specified timepoints
Simultaneously, it activates extracellular signal-regulated kinase (ERK1/2) pathways while reducing pro-inflammatory nuclear factor kappa B (NF-B) signaling a combination that supports tissue recovery while managing inflammation
Pathogenesis Unknown but origin from liver blastema cells, neoplastic hepatocytes, oval cells, and biliary epithelial cells proposed
Nutritional priorities to support GLP-1 therapy include focusing on nutrient dense foods that complement the effects of GLP-1 on metabolism and brain function
To use the Trulicity Pen remove the cap of the pen and hold the pen straight up and down on the skin before pushing the green injection button
